SCHEMBL6903087

SCHEMBL6903087

O=C(CP(c1ccccc1)c1ccccc1)CP(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
CES1 P23141 4/20 0.37
CES2 O00748 3/20 0.37
ALOX15 P16050 2/20 0.37
MAPK1 P28482 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
AKR1B1 P15121 1/20 0.37
ALDH1A1 P00352 4/20 0.36
DAO P14920 1/20 0.36
TSHR P16473 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
GSK3B P49841 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28674793 0.87 HSD11B1 (0.44) TDP1CES1CES2MAPTHPGD
SCHEMBL1009627 0.85 AKR1B1 (0.42) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL28457741 0.85 ALDH1A1 (0.33) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL27550664 0.83 AKR1B1 (0.41) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL9518462 0.83 AKR1B1 (0.41) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL28768934 0.83 AKR1B1 (0.41) CYP3A4TDP1CES1CES2ALOX15
Ammonia Solution, Strong SCHEMBL31339446 0.83 AKR1B1 (0.41) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL9389962 0.81 MAPT (0.41) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL28307265 0.81 AKR1B1 (0.39) CYP3A4TDP1CES1CES2ALOX15
SCHEMBL4861260 0.81 ALDH1A1 (0.43) CYP3A4TDP1CES1CES2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6835850-B2 Reacting a conjugated diene with carbon monoxide and an alcohol to form an alkenoic ester by using a durable catalyst complex of palladium cations, a ligand of bridged phospha-cycloalkanes and source of anions; by-product inhibition DSW IP ASSETS B.V. (NL) 2004-12-28 US disclosed
US-20040039226-A1 Process for the carbonylation of a conjugated diene DSM IP ASSETS B.V. (NL) 2004-02-26 US disclosed
US-6268530-B1 SEPARATING LINEAR 5-FORMYLVALERIC ACID FROM MIXTURE OF 5- AND 3-AND/OR 4-BRANCHED FORMYLVALERIC ACIDS BY SEPARATING FRACTIONAL EXTRACTION WITH TWO IMMISCIBLE SOLVENTS DSM N.V. (NL) 2001-07-31 US disclosed
US-6175036-B1 CATALYZING THE CARBOXYLATION OF AN ALKOXY-BUTENE WITH CARBON MONOXIDE IN THE PRESENCE OF A CATALYST SYSTEM COMPRISING PALLADIUM, A PHOSPHORUS LIGAND AND AN ACID PROMOTOR DSM N.V. (NL) 2001-01-16 US disclosed
EP-0836588-B1 PROCESS TO PREPARE 5-FORMYLVALERIC ACID DSM NV (NL) 2000-05-17 EP disclosed
US-6013816-A HYDROFORMYLATING UNSATURATED C.SUB.4-C.SUB.12 CARBOXYLIC ACID, ESTER, OR NITRILE TO PRODUCE LINEAR .OMEGA.-FORMYL-CARBOXYLIC ACID OR LINEAR FORMYL NITRILE IN PRESENCE OF WATER, CARBON MONOXIDE, HYDROGEN AND CATALYST DSM NV (NL) 2000-01-11 US disclosed
EP-0742788-B1 PROCESS FOR THE PREPARATION OF A LINEAR FORMYL COMPOUND DSM NV (NL) 1999-03-31 EP disclosed
EP-0662468-B1 Process for the preparation of 5-formylvalerate DSM NV (NL) 1998-05-06 EP disclosed
EP-0836588-A1 PROCESS TO PREPARE 5-FORMYLVALERIC ACID DSM N.V. (NL) 1998-04-22 EP disclosed
WO-1997002228-A1 PROCESS TO PREPARE 5-FORMYLVALERIC ACID DSM N.V. (NL) 1997-01-23 WO disclosed
EP-0341773-A1 Process for the preparation of lactones SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-11-15 EP disclosed
EP-0220767-B1 PROCESS FOR THE PREPARATION OF ALDEHYDES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-11-02 EP disclosed
US-4861912-A Process for the preparation of a diester of adipic acid SHELL OIL COMPANY (US) 1989-08-29 US disclosed
US-4849542-A Process for the preparation of oxo-alkanedioic acids or diesters thereof SHELL OIL COMPANY (US) 1989-07-18 US disclosed
EP-0293999-A2 Process for the coproduction of anilines and oxamides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-12-07 EP disclosed
EP-0293053-A2 Process for the preparation of cyclic carboxylic anhydrides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-11-30 EP disclosed
EP-0284170-A1 Process for the preparation of a diester of adipic acid SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-09-28 EP disclosed
US-4731487-A Process for the preparation of aldehydes SHELL OIL COMPANY (US) 1988-03-15 US disclosed
EP-0250037-A2 Process for the preparation of urea derivatives and catalyst system SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-12-23 EP disclosed
EP-0220767-A1 Process for the preparation of aldehydes SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039226-A1 Process for the carbonylation of a conjugated diene ROS1, DOHH, NOXO1 CYP3A4 209/4885TDP1 2645/4885CES1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.